- Home
- BTAI vs IGC Comparison
BTAI vs IGC Comparison
Compare BTAI & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTAI | IGC |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 31.5M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BTAI | IGC |
|---|---|---|
| Price | $1.07 | $0.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.00 | $5.25 |
| AVG Volume (30 Days) | ★ 1.0M | 967.4K |
| Earning Date | 05-11-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.63 | 59.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $197.82 | N/A |
| Revenue Next Year | $910.15 | $13.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.24 |
| 52 Week High | $8.08 | $0.50 |
Technical Indicators
Market Signals| Indicator | BTAI | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 64.72 |
| Support Level | N/A | $0.32 |
| Resistance Level | $1.26 | $0.44 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 24.49 | 78.80 |
Price Performance
Historical ComparisonAbout BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.